我如何个性化治疗慢性阶段的CML?
Ariel Monet Leyte-Vidal1, Neil P Shah1
1University of California, San Francisco, San Francisco, California, United States.
Blood
|April 16, 2025
概括
选择最好的慢性髓性白血病 (CML) 的初始治疗方法需要平衡有效性,耐受性和长期结果. 患有CML的患者现在有多种向治疗选择,改善了生存率.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 慢性髓性白血病 (CML) 治疗在向治疗方面取得了重大进展.
- BCR::ABL1氨酸激酶抑制剂 (TKI) 对新诊断的慢性阶段CML非常有效.
- 目前的CML疗法提供了优异的长期存活率,与年龄匹配的对照相比.
研究的目的:
- 审查对慢性髓性白血病的前线向治疗的情况.
- 讨论影响初始CML治疗选择的关键因素.
- 强调平衡疗效与患者生活质量和治疗成本的重要性.
主要方法:
- 对CML治疗指南和临床试验数据的现有文献的审查.
- 对可用的BCR::ABL1 TKIs的疗效,耐受性和长期结果的分析.
- 讨论治疗选择中的以患者为中心的因素.
主要成果:
- 对于新诊断的慢性阶段CML,有五种有效且耐受良好的BCR::ABL1TKI可用.
- 现在,CML患者的长期存活率很好,接近一般人群的长期存活率.
- 大多数CML患者通常需要终身治疗.
结论:
- 选择前线CML治疗需要仔细考虑初始疗效之外的多个因素.
- 响应的耐用性,耐受性,生活质量和避免毒性是至关重要的.
- 治疗的简单性和成本对患者和医疗保健系统来说是越来越重要的考虑因素.
相关概念视频
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Differentiation of Common Myeloid Progenitor Cells
3.1K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.1K


